Clinical Trials Logo

Optic Nerve Diseases clinical trials

View clinical trials related to Optic Nerve Diseases.

Filter by:

NCT ID: NCT00759174 Completed - Clinical trials for Optic Neuropathy, Ischemic

A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

Start date: November 2008
Phase:
Study type: Observational

The objective of this non-interventional study is to examine whether use of Phosphodiesterase Inhibitors (PDE5s), including use of sildenafil, vardenafil, or tadalafil, triggers the onset of acute NAION.

NCT ID: NCT00747487 Completed - Clinical trials for Leber's Hereditary Optic Neuropathy

Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic Neuropathy

RHODOS
Start date: November 2007
Phase: Phase 2
Study type: Interventional

This study is meant to assess the effectiveness of idebenone on visual function measures in patients with Leber's Hereditary Optic Neuropathy over a 6 months period.

NCT ID: NCT00561834 Completed - Clinical trials for Nonarteritic Anterior Ischemic Optic Neuropathy

Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy

NAION
Start date: November 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to explore the safety and efficacy of ranibizumab to treat non-arteritic ischemic optic neuropathy based on clinical and anatomical findings.

NCT ID: NCT00528151 Completed - Clinical trials for Optic Atrophy, Hereditary, Leber

A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON)

Start date: May 2005
Phase: Phase 3
Study type: Interventional

Background Leber's Hereditary Optic Neuropathy (LHON) is a maternally inherited ocular disorder associated with a mutation in mtDNA . The common manifestation is visual loss which caused by the respiratory chain enzymes complex dysfunction resulting in increased oxidative stress enzymes production. Purpose To determine whether curcumin which is an antioxidant agent is beneficial to the patients with 11778 LHON mutation. Material and Method Seventy patients with 11778 LHON mutation were randomly treated with oral curcumin (500 mg/day) and placebo for 1 year. The visual acuity, computerized visual field, electrophysiologic parameters and oxidative stress enzymes in plasma were compared before and after treatment at 3, 6, and 12 months interval.

NCT ID: NCT00450294 Completed - Clinical trials for Intraocular Pressure

Intraocular Pressure During Abdominal Aortic Aneurysm (AAA) Repair

Start date: March 2007
Phase: N/A
Study type: Observational

The objective of this study will be to answer a clinical question that has not already been investigated; that is, what are the effects of aortic infra-renal clamping and unclamping on intraocular pressure during Abdominal Aortic Aneurysm (AAA) repair? Depending on the results, this study may raise or alleviate concern that vascular surgery for abdominal aortic aneurysm could contribute to early perioperative exacerbation of pre-existing eye disease and increase a patient's vulnerability to developing a type of blindness known as ischemic optic neuropathy. The purpose of this observational study is to evaluate whether intraocular pressure measurements with a handheld tonometer will detect changes in intraocular pressure related to intraoperative events during aortic cross clamping and unclamping that may provide information on causes of perioperative blindness.

NCT ID: NCT00432393 Completed - Clinical trials for Nonarteritic Anterior Ischemic Optic Neuropathy

Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy

Start date: June 2002
Phase: Phase 4
Study type: Interventional

Purpose: There are some controversies about the effect of Levodopa-Carbidopa on treatment of non-arteritic anterior ischemic optic neuropathy (NAION). This study was performed to evaluate the effect of Levodopa-Carbidopa on visual acuity, color vision, and visual field in patients with recent onset NAION (less than 6 weeks duration). Patients and Methods: In this double-blind randomized clinical trial, 13 patients were treated with levodopa-carbidopa and 12 patients took placebo for 3 weeks. Visual acuity, color vision, and visual field were tested before and at 4th, 12th, 16th, and 24th weeks after enrollment, and evaluated.

NCT ID: NCT00404729 Completed - Glaucoma Clinical Trials

Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases

Start date: February 28, 2005
Phase: Phase 4
Study type: Interventional

In the management of glaucoma, as for as in other optic nerve diseases, an important goal of ophthalmologists is represented by the possibility of influencing visual function. In this regard, Parisi et al [Ophthalmology 1999; 106:1126-1134.] suggested the intramuscular treatment with Cytidine-5-diphosphocholine (CDP-Choline or citicoline) to improve glaucomatous visual defects. In particular, recent studies reported the effects of citicoline on glaucomatous retinal and postretinal visual structures evaluated by electrophysiological examinations (PERG and VEP). It was observed that a 2-month period of treatment with citicoline may induce improvement in both ganglion cell function (PERGs with increase in amplitudes and shortening in times-to-peak) and in neural conduction along postretinal visual pathways (VEPs with increase in amplitudes and shortening in times-to-peak). The effects of citicoline on glaucomatous retinal and postretinal structures were not present 8 months after the end of treatment. However, performing several 2-month period of treatment with citicoline during a total period of 8 years, it was found a additional improvement of the glaucomatous retinal and postretinal impairment [Parisi V. Doc Ophthalmol. 2005 Jan;110:91-102). In this work, the investigators aimed to assess whether there similar visual function outcomes can be reached by the oral treatment with citicoline in patients affected by glaucomatous optic nerve disease as of as in other optic nerve diseases (i.e. non-arteritic ischemic optic neuropathy)

NCT ID: NCT00372021 Completed - Clinical trials for Non Arthritic Anterior Ischemic Optic Neuropathy

Neurotomy of Optic Nerve in Non-Arthritic Anterior Ischemic Optic Neuropathy

Start date: January 2003
Phase: Phase 1/Phase 2
Study type: Interventional

Non-arthritic anterior ischemic optic neuropathy is the most common cause of sudden visual loss due to optic nerve involvement in patients above 50 years old. As this problem can be considered as a sclera out let syndrome an there is no effective and successful treatment for it, we decided to do a neurotomy procedure and relax the involved optic nerve in order to achieve acceptable treating outcome.

NCT ID: NCT00359632 Terminated - Clinical trials for Optic Nerve Diseases

Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater

Start date: November 2008
Phase: Phase 3
Study type: Interventional

To understand and characterize the effects of linezolid on the optic nerve by observing and following patients who have been treated with linezolid for six weeks or longer for the development of signs or symptoms of visual disturbance or eye disorders.

NCT ID: NCT00140491 Completed - Clinical trials for Non-Arteritic Anterior Ischemic Optic Neuropathy

Vision Restoration Therapy (VRT) to Treat Non-Arteritic Anterior Ischemic Optic Neuropathy

Start date: August 2005
Phase: N/A
Study type: Interventional

The goal of this pilot study is to evaluate the effect of Vision Restoration Therapy, VRT, on the visual function of patients with unilateral or bilateral AION, who have good central vision (at least 20/60) and altitudinal visual field defects.